fda approves semaglutide weight-loss drug Wegovy to reduce heart-disease risks FDA approves Wegovy weight-loss GLP-1

You wake up

Providing adolescents with obesity another option Wegovy is the only once-weekly injectable GLP-1 RA indicated to reduce excess body weight and maintain weight reduction long term in combination with diet and exercise in adolescents with obesity aged 12 years and older 3 The safety and effectiveness of Wegovy injection have not been established in pediatric patients to reduce the risk of major adverse CV events or to reduce excess body weight and maintain weight reduction long term in those less than 12 years of age

Blum-Degena, D

- Easy to use without the worry of adding too much or too little water

W.BrandmeirN

All products supplied by NewBioRx are intended strictly for laboratory research and development use only and are not approved for human or veterinary use